Plasma Kallikrein Inhibitor Screening Kit (Colorimetric)

Plasma Prekallikrein (EC 3.4.21.34), is the glycosylated single chain zymogen precursor of the plasma serine protease Kallikrein (PK). It circulates with kininogen and is activated by Factor XIIa to Kallikrein in the intrinsic coagulation pathway. Kallikrein activates plasminogen in fibrinolysis and cleaves kininogen in the bradykinin system of vasodilation. Prekallikrein deficiency is rare and causes increased activated partial thromboplastin time. Elevated plasma Prekallikrein is associated with diabetes and cardiovascular disease. Plasma Kallikrein inhibitors have been proposed as drugs to manage Hereditary Angioedema. BioVision’s Plasma Kallikrein Inhibitor Screening Kit utilizes the ability of active Plasma Kallikrein to cleave a synthetic pNA-based peptide substrate to release pNA (OD405 nm), which can be easily quantified using a microplate reader. In the presence of a Plasma Kallikrein inhibitor, the cleavage of this substrate is reduced/abolished resulting in decrease or total loss of the pNA absorbance. This simple and high-throughput adaptable assay kit can be used to screen/study/characterize potential inhibitors of Plasma Kallikrein.

• Detection method: Colorimetric (OD 405 nm) • Application:Screening/characterizing/studying Plasma Kallikrein inhibitors/activators

• Simple and reliable test to screen Plasma Kallikdrein inhibitors/activators • High-throughput compatible • Includes Inhibitor Control

Proteases

none

• PK Assay Buffer • Human PK • PK Substrate • PK Inhibitor (1 mU/µl)

-20°C

gel pack

12 months

Mammalian

Screening/characterizing/studying Plasma Kallikrein inhibitors/activators

Colorimetric assays or detection use UV absorption or enzymatic color reaction.

Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.